Literature DB >> 19562748

FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype.

Felicetto Ferrara, Clelia Criscuolo, Cira Riccardi, Tiziana Izzo, Mariangela Pedata, Carolina Copia, Laura Vicari, Marina Tarsitano, Salvatore Palmieri, Fabrizio Pane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19562748     DOI： 10.1002/ajh.21458

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  8 in total

1.  Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.

Authors:  Meir Wetzler; Krzysztof Mrózek; Jessica Kohlschmidt; Hervé Dombret; Hartmut Döhner; Sylvain Pilorge; Utz Krug; Andrew J Carroll; Richard A Larson; Guido Marcucci; Wolfgang Hiddemann; Thomas Büchner; Clara D Bloomfield
Journal:  Haematologica       Date:  2013-10-04       Impact factor: 9.941

2.  Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

Authors:  Betül Oran; Antonio M Jimenez; Marcos De Lima; Uday R Popat; Roland Bassett; Borje Andersson; Gautam Borthakur; Qaiser Bashir; Julianne Chen; Stefan O Ciurea; Elias Jabbour; Jorge Cortes; Partow Kebriaei; Issa F Khouri; Muzaffar H Qazilbash; Farhad Ravandi; Gabriela Rondon; Xinyan Lu; Elizabeth J Shpall; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-31       Impact factor: 5.742

3.  FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Susan P Whitman; Kati Maharry; Michael D Radmacher; Heiko Becker; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Yue-Zhong Wu; Sebastian Schwind; Klaus H Metzeler; Jing Wen; Maria R Baer; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Joseph O Moore; Richard M Stone; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2010-07-23       Impact factor: 22.113

4.  Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.

Authors:  Harshabad Singh; Salma Asali; Lillian L Werner; Daniel J DeAngelo; Karen K Ballen; Philip C Amrein; Martha Wadleigh; Ilene Galinsky; Donna S Neuberg; Edward A Fox; Richard M Stone; Eyal C Attar
Journal:  Leuk Res       Date:  2011-06-21       Impact factor: 3.156

5.  Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.

Authors:  Joseph M Brandwein; Michelle Geddes; Jeannine Kassis; Andrea K Kew; Brian Leber; Thomas Nevill; Mitchell Sabloff; Irwindeep Sandhu; Andre C Schuh; John M Storring; John Ashkenas
Journal:  Am J Blood Res       Date:  2013-05-05

Review 6.  Frontline therapy of AML: should the older patient be treated differently?

Authors:  James M Foran
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

Review 7.  A precision medicine approach to management of acute myeloid leukemia in older adults.

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Vijaya Raj Bhatt
Journal:  Curr Opin Oncol       Date:  2020-11       Impact factor: 3.915

8.  Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Authors:  Victoria V Prassek; Maja Rothenberg-Thurley; Maria C Sauerland; Tobias Herold; Hanna Janke; Bianka Ksienzyk; Nikola P Konstandin; Dennis Goerlich; Utz Krug; Andreas Faldum; Wolfgang E Berdel; Bernhard Wörmann; Jan Braess; Stephanie Schneider; Marion Subklewe; Stefan K Bohlander; Wolfgang Hiddemann; Karsten Spiekermann; Klaus H Metzeler
Journal:  Haematologica       Date:  2018-06-14       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.